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Abstract
Background: Two-hydroxyglutarate (2HG) is present at low concentrations in healthy mammalian cells as both an
L and D enantiomer. Both the L and D enantiomers have been implicated in regulating cellular physiology by
mechanisms that are only partially characterized. In multiple human cancers, the D enantiomer accumulates due
to gain-of-function mutations in the enzyme isocitrate dehydrogenase (IDH) and has been hypothesized to drive
malignancy through mechanisms that remain incompletely understood. While much attention has been dedicated
to identifying the route of 2HG synthesis, the metabolic fate of 2HG has not been studied in detail. Yet the
metabolism of 2HG may have important mechanistic consequences influencing cell function and cancer
pathogenesis, such as modulating redox potential or producing unknown products with unique modes of action.
Results: By applying our isotope-based metabolomic platform, we unbiasedly and comprehensively screened for
products of L- and D-2HG in HCT116 colorectal carcinoma cells harboring a mutation in IDH1. After incubating
HCT116 cells in uniformly 13C-labeled 2HG for 24 h, we used liquid chromatography/mass spectrometry to track
the labeled carbons in small molecules. Strikingly, we did not identify any products of 2HG metabolism from the
thousands of metabolomic features that we screened. Consistent with these results, we did not detect any
significant changes in the labeling patterns of tricarboxylic acid cycle metabolites from wild type or IDH1 mutant
cells cultured in 13C-labeled glucose upon the addition of L, D, or racemic mixtures of 2HG. A more sensitive,
targeted analysis revealed trace levels of isotopic enrichment (<1 %) in some central carbon metabolites from
13C-labeled 2HG. However, we found that cells do not deplete 2HG from the media at levels above our
detection limit over a 48 h time period.
Conclusions: Taken together, we conclude that 2HG carbon is not readily transformed in the HCT116 cell line. These
data indicate that the phenotypic alterations induced by 2HG are not a result of its metabolic products.
Keywords: 2-Hydroxyglutarate, Cancer metabolism, Mass spectrometry, Metabolomics, Isotope-based
metabolomics, 13C-tracing
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Background
Two-hydroxyglutarate (2HG) is an endogenous metabolite
that can occur naturally as either the L-(S)-enantiomer or
the D-(R)-enantiomer [1]. Both enantiomers occur at low
concentrations in healthy, mammalian cells and can be
detected in patient biofluids [2]. The metabolic pathways
responsible for producing low concentrations of 2HG in
healthy cells remain incompletely characterized, but pro-
miscuous utilization of alpha-ketoglutarate by phospho-
glycerate dehydrogenase, lactate dehydrogenase A, and
malate dehydrogenase has been implicated [3–5]. Produc-
tion of low levels of 2HG in healthy cells has thus been
hypothesized to be a result of unwanted side reactions,
although recent evidence suggests that 2HG in healthy
cells may have some regulatory functions [5–7].
It is thought that when small amounts of 2HG are pro-
duced in healthy cells, the 2HG is metabolized by L-2HG
dehydrogenase or D-2HG dehydrogenase [8]. These 2HG
dehydrogenases transform 2HG into alpha-ketoglutarate
and have been referred to as a type of “house-cleaning en-
zyme.” Indeed, defects in either dehydrogenase lead to
rare inborn errors of metabolism in which pathological
levels of 2HG accumulate. More recently, the observation
was made that D-2HG also accumulates in cancer cells
which harbor gain-of-function mutations in isocitrate de-
hydrogenase (IDH) 1 and 2 [9]. It has now been shown
that D-2HG producing IDH1 and IDH2 mutations
occur in many glioma, acute myeloid leukemia, chondro-
sarcoma, cholangiocarcinoma, and T cell angioimmuno-
blastic lymphoma cancers [10]. Interestingly, D-2HG
accumulates in these cancers despite the presence of a
presumably functional D-2HG dehydrogenase.
Increased concentrations of L-2HG and D-2HG both
lead to altered cellular phenotypes [8]. D-2HG is some-
times referred to as an “oncometabolite” because its
accumulation is thought to contribute to cancer patho-
genesis [11]. Most important to the current study, we
note that the mechanisms by which L-2HG and D-2HG
regulate cellular physiology are not well understood.
While increased L-2HG and D-2HG both have been
shown to inhibit alpha-ketoglutarate-dependent dioxy-
genase enzymes that modify chromatin, it has also been
suggested that D-2HG drives cancer pathogenesis by
other non-epigenetic mechanisms that have yet to be
characterized [5, 12–16]. Additionally, the proposed epi-
genetic mechanisms alone do not adequately address the
context dependency and dose specificity of accumulated
2HG on cellular physiology [11].
To better understand the mechanisms by which
elevated 2HG influences cellular physiology, the object-
ive of this work was to explore the possibility that 2HG
is transformed into unexpected products. By applying
cutting-edge metabolomic technologies, thousands of
small molecules can be quantitatively assessed [17].
Some of these small molecules correspond to unknown
metabolites that have not been characterized with respect
to structure, pathway, and biochemical function [18, 19].
Given that products of 2HG may have metabolic effects
themselves, mapping 2HG metabolism is an important ad-
vance in understanding 2HG biology. In addition to track-
ing 2HG carbon into potentially unexpected metabolites,
we also sought to assess the transformation of 2HG into
the tricarboxylic acid (TCA) cycle via alpha-ketoglutarate
as we speculated that this reaction could regulate cellular
phenotype by modulating redox potential. Notably, in the
HCT116 colorectal carcinoma cells that we studied here,
we did not find evidence of significant L-2HG or D-2HG
metabolism over a 48 h time course.
Methods
Materials
All liquid chromatography solvents and additives were
obtained from Sigma-Aldrich (St. Louis, MO), as well as
all chemicals needed for the synthesis of 2HG. Stable
isotope-labeled alpha-ketoglutarate was purchased from
Cambridge Isotope Laboratories (Tewksbury, MA). Cell
culture media and reagents were purchased from Life
Technologies (Grand Island, NY), and IDH1 (R132H/+)
cells were purchased from Horizon Discovery Ltd.
(Cambridge, UK). An enzyme-linked immunosorbent
assay (ELISA) kit for measuring D-2HG dehydrogenase
was purchased from Cloud Clone Corp. (Houston, TX).
2HG synthesis
Racemic uniformly 13C-labeled 2HG (U-13C 2HG) was
synthesized by reducing one equivalent of U-13C-labeled
alpha-ketoglutarate with three equivalents of sodium bo-
rohydride in water. The alpha-ketoglutarate was first dis-
solved in water and cooled to 0 °C in an ice bath, then
sodium borohydride was slowly added as a solid over ap-
proximately 10 min. The mixture was warmed to room
temperature and stirred for 2 h, then quenched with an
equal volume of 1 M HCl, and dried via rotary evapor-
ation under reduced pressure. To remove excess borates,
the resulting solid was suspended in high performance
liquid chromatography (HPLC) grade methanol, filtered,
concentrated to dryness, and stored at −20 °C. The
structure and purity of synthetic U-13C 2HG was con-
firmed by 1H-NMR and LC/MS/MS. Trace amounts of
fully labeled starting material were detected by LC/MS/
MS. These were present at >1000-fold lower levels than
U-13C 2HG and were too low in concentration to be de-
tected by 1H-NMR.
Cell culture
Wild type HCT116 and HCT116 R132H/+ cells were
cultured in McCoy’s 5A Modified Medium with 10 %
fetal bovine serum (FBS) and no antibiotics, at 37 °C
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with 5 % CO2. For uniformly
13C-labeled glucose (U-13C
glucose) experiments, cells were grown in glucose-free
DMEM supplemented with either 25 mM U-13C glucose
or 25 mM non-labeled glucose. Cells were seeded in a
10-cm plate at a density of approximately 2 × 106 cells in
10 mL of media.
Protein assay
An ELISA experiment was performed to test for the pres-
ence of D-2HG dehydrogenase in HCT116 R132H/+ cells.
HeLa cells, which have been reported to have D-2HG de-
hydrogenase, were used as a reference control [20]. Sam-
ples were prepared by centrifuging trypsinized cells, re-
suspending in ice-cold phosphate buffered saline (PBS),
and centrifuging again. The final cell pellet was re-
suspended in 1 mL of ice-cold PBS and subjected to three
repeated freeze-thaw cycles to break apart cellular compo-
nents. After the final thaw, the sample was centrifuged
and the supernatant was collected for analysis.
Isotope tracing
HCT116 R132H/+ cells were plated 24 h prior to being
administered U-13C 2HG. After 24 h, cells were grown
in media supplemented with 10 % of 50 mM U-13C 2HG
in PBS or 10 % of 50 mM non-labeled 2HG in PBS
(yielding a final concentration of 5 mM 2HG) and har-
vested after a total of 48 h. When harvesting, medium
was first aspirated then flash frozen in liquid nitrogen.
Cells were washed with PBS three times, then HPLC
grade water once, and quenched with 1 mL of ice-cold
HPLC grade methanol. Cells were then scraped from the
plate in methanol, pelleted, and dried via SpeedVac and
lyophilization. The dry samples were weighed and normal-
ized by dry mass. Samples were extracted by methods as
we have described previously [21, 22]. Briefly, lyophilized
cell pellets were re-suspended in methanol/acetonitrile/
water (2:2:1) at 1 mL of solvent per 1 mg dry cell mass.
After extraction, supernatants were dried on a SpeedVac
and re-suspended in acetonitrile/water (1:1). The final
solvent volume was normalized on the basis of dry mass,
with a ratio of 100 μL per 1 mg dry cell mass.
Measuring 2HG dilution of 13C-glucose labeling
HCT116 parent cells and HCT116 R132H/+ cells were
plated 36 h prior to being administered exogenous non-
labeled 2HG and U-13C glucose. After 36 h, cells were
grown in media supplemented with 10 % FBS and
25 mM of either U-13C glucose or non-labeled glucose.
At this time, cells were treated with either (i) 10 % of
25 mM L- or D-2HG, (ii) 10 % of 50 mM L- or D-2HG,
or (iii) 10 % of 50 mM L- and D-2HG. Cells were then
harvested after a labeling period of 12 h and extracted as
described above.
Liquid chromatography/mass spectrometry
Following extraction, 5 μL of each sample was injected
onto a Luna Aminopropyl column (3 μm, 150 mm ×
1.0 mm I.D., Phenomenex, Torrance, CA) connected to
an Agilent 1260 capillary HPLC system (Santa Clara,
CA) set to a flow rate of 50 μL/min. Mobile phase A
consisted of 95 % water, 5 % acetonitrile (ACN), 20 mM
ammonium hydroxide, and 20 mM ammonium acetate.
Mobile phase B consisted of 95 % ACN and 5 % water.
The column was kept at room temperature while the
following linear gradients were applied: 0–5 min, 100 %
B; 5–45 min, 100–0 % B; 45–50 min, 0 % B; 50–51 min,
0–100 % B; and 51–60 min, 100 % B. MS detection was
performed by using an Agilent 6540 Q-TOF with an
electrospray ionization (ESI) source and Agilent Jet
Stream technology, mass range 50–1700m/z. The fol-
lowing source parameters were used: drying gas
temperature 300 °C, drying gas flow 9 L/min, nebulizer
pressure 35 psi, sheath gas temperature 350 °C, sheath
gas flow 11 L/min, capillary voltage 3000 V, and nozzle
voltage 1000 V. A fragmentor voltage of 175 V was ap-
plied. Conventional liquid chromatography/mass spec-
trometry (LC/MS)-based metabolomic analyses were
performed in negative ionization mode only. After intro-
duction of labeled 2HG to cells, metabolites were ex-
tracted and profiled to identify possible 2HG products in
both negative and positive ionization modes. Metabolite
identifications were confirmed by comparing experimen-
tal retention time and fragmentation data to model stan-
dards. With the methods applied, citrate and isocitrate
could not be resolved.
For improved sensitivity, we also performed targeted
analysis of some key metabolites (alpha-ketoglutarate,
fumarate, malate, and citrate) and evaluated isotopic
enrichment manually. Targeted analyses were performed
by injecting 3 μL of sample onto a Luna Aminopropyl
column (same as described above) connected to a
Dionex UltiMate 3000 UHPLC system, set to a flow rate
of 50 μL/min with the same gradient as stated above.
MS detection was performed with a Thermo Scientific Q
Exactive Plus bench-top quadrupole-Orbitrap mass
spectrometer in negative ionization mode at 140,000 re-
solving power by using selected ion monitoring (SIM).
Quantification of 2HG and glutamine was performed
on an Agilent 6490 triple quadrupole instrument in
negative ion mode, using multiple reaction monitoring
(MRM). Sample aliquots of 0.3 μL were injected onto an
Acquity UPLC BEH Amide column (1.7 μm, 2.1 ×
50 mm I.D., Waters Corporation, Milford MA) con-
nected to an Agilent 1290 Infinity UHPLC system set to a
flow rate of 0.6 mL/min. Mobile phase A consisted of
50 % water, 50 % ACN, 0.4 % ammonium hydroxide, and
10 mM ammonium acetate. Mobile phase B consisted of
95 % ACN and 5 % water. The following linear gradient
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was applied: 0–1.0 min, 85 % B; 1.0–1.35 min, 60 % B;
1.35–1.4 min, 50 % B; 1.4–1.8 min, 50 % B; 1.8–3.0 min,
75 % B; and 3.0–6.0 min, 100 % B. The following source
parameters were used: drying gas temperature 125 °C, dry-
ing gas flow 13 L/min, nebulizer pressure 55 psi, sheath
gas temperature 400 °C, sheath gas flow 12 L/min, capil-
lary voltage 2000 V, and nozzle voltage 0 V. For 2HG, the
quantifier ion transition m/z 147.0→ 129.0 and the quali-
fier 147.0→ 101.0 were used with a fragmentor voltage of
100 V, a collision energy of 10 V, and a cell accelerator
voltage of 3 V. For glutamine, the quantifier ion transition
m/z 145.0→ 127.0 and the qualifier 145.0→ 109.0 were
used with a fragmentor voltage of 120 V, a collision energy
of 10 V, and a cell accelerator voltage of 3 V.
Measuring 2HG consumption rate from media
HCT116 (parent) cells were plated in 3 mM unlabeled
D-2HG and cultured for 48 h. LC/MS analysis was used
to measure 2HG and glutamine in the media at 0, 24,
and 48 h. The concentration of 2HG and glutamine was
quantified at all time points using a standard curve to
determine the rate of consumption. This was compared
to plates containing only media (no cells) to account for
non-cellular degradation occurring over the given time
period. For this assay, we ignored intracellular contribu-
tions of 2HG and glutamine as they were negligible
compared to the levels of 2HG and glutamine in the
media. Media samples were extracted as described above.
Data processing
Raw data was converted to mzXML by using mscon-
vert and then analyzed with the XCMS software
(peakwidth = 5–140 s and ppm = 12) [23]. For isotope
analysis, our in-house X13CMS software package was uti-
lized and isotopic labeling patterns were identified with
the following parameters: mass of 12C = 12.000000 Da,
mass difference between 13C and 12C = 1.003355 Da,
ppm = 20, RTwindow = 10 s, and noiseCutoff = 8000 ion
counts [24]. Some key metabolites (e.g., the TCA cycle
intermediates) were also inspected manually.
Statistical analysis
All experiments were performed in replicates of three
(n = 3 per group). Each labeling experiment was
performed in parallel with pairs of equivalent non-la-
beled cultures. Samples were evaluated with a Student’s
paired t test, with acceptable p values being less than 0.05.
Results
Global metabolomic comparison of IDH1 mutant cells to
wild type controls
This study focuses on one cell line, HCT116 colorectal
carcinoma. To first assess the potential effects of 2HG on
these particular cells, we compared the parent HCT116
cell line to an isogenic cell line with heterozygous knock-
in of a mutant allele of IDH1 (R132H). By using conven-
tional LC/MS-based metabolomics, we detected 12,481
features from the cells with our in-house XCMS/
Warpgroup software [25]. Here, we define a feature as an
ion detected with a unique mass-to-charge ratio and re-
tention time [17]. We found that 991 of the detected fea-
tures had increased intensities and 731 had decreased
intensities in IDH1 mutant cells relative to the parent
cells, with a p value <0.05 and a fold change >1.5 (Fig. 1).
As expected, a feature identified as 2HG was found to be
increased with a fold change of 165 in the IDH1 mutant
cells relative to the parent cells (see green arrow in Fig. 1).
The results confirm that the IDH1 mutation has a meta-
bolic effect in these cells. We hypothesized that the altered
features in IDH1 mutant cells were a result of the re-
routing of nutrients for 2HG synthesis, products of 2HG
metabolism, and/or effects of 2HG that are independent
of its metabolism (e.g., enzymatic inhibition). The object-
ive of this study was to find products of 2HG metabolism,
which we predicted might be increased in the IDH1 mu-
tant dataset from the current experiment. Given the com-
plexity of metabolic regulation, however, it is not possible
to identify 2HG products from these data directly. We
note that no significant alterations were found in citrate/
isocitrate, fumarate, and glutamate. These metabolites are
expected to be closely upstream or downstream of 2HG
based on pathway maps and therefore might have been
predicted to be elevated if 2HG was being metabolized via
this route. This result led us to further investigate which,
if any, of the increased metabolic features in IDH1 mutant
cells are products of 2HG transformation. To find prod-
ucts of 2HG transformation, we applied isotope-based
metabolomic technologies as described below.
Unbiased metabolomic screening identifies no products
of 2HG metabolism
To track the fate of 2HG using our isotope-based
metabolomic platform, we needed U-13C-enriched
2HG (Fig. 2). We synthesized U-13C 2HG from U-13C
alpha-ketoglutarate obtained from Cambridge Isotope
Laboratories as described in Methods. Successful synthesis
of 2HG was validated by comparing the accurate mass,
tandem mass spectra, and retention time of the synthe-
sized compound to that of an authentic model compound
purchased from Sigma-Aldrich (Fig. 2a). Our synthesis re-
sulted in a racemic mixture of both U-13C L-2HG and U-
13C D-2HG.
Next, we gave HCT116 R132H/+ cells either U-13C 2HG
or non-labeled 2HG, which was synthesized from non-
labeled alpha-ketoglutarate by using the same preparative
method (Fig. 3). Metabolites from cells treated with U-13C
2HG or non-labeled 2HG for 24 h were then isolated, ana-
lyzed by LC/MS, and the results compared by using the
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X13CMS software as described previously [24, 26, 27]. Mul-
tiplexed metabolite extractions were used to increase the
number of compounds detected. Out of the more than
25,000 features screened, less than 20 were found to be dif-
ferent between the U-13C 2HG and non-labeled 2HG sam-
ple groups (Fig. 3a). One of the differences was found to be
2HG, which was enriched at the 35 % level (Fig. 4a). This
result shows that 2HG was successfully transported into
the cells. All other features found to be different between
the sample groups had the same retention time and chro-
matographic profiles as 2HG, suggesting that they are in-
source fragments/adducts of 2HG and not products of cel-
lular 2HG metabolism [28]. This was verified by showing
that a pure 2HG standard produced the same features
when analyzed under identical LC/MS conditions.
These data suggest that neither L-2HG nor D-2HG
are significantly metabolized over 24 h in colorectal can-
cer cells. As a positive control to demonstrate that our
platform can effectively identify molecular transforma-
tions, we next fed the same colorectal carcinoma cells
either U-13C glutamine or non-labeled glutamine for
24 h. We then isolated the metabolites, analyzed them
by LC/MS, and used our X13CMS software to compare
the labeled and non-labeled glutamine sample groups. In
contrast to the 2HG experiments, we identified hun-
dreds of metabolomic features that were altered between
cells given labeled and non-labeled glutamine (Fig. 3b).
The majority of these alterations had retention times
unique from glutamine and corresponded to metabolites
produced from glutamine carbon by cellular metabolism.
Fig. 2 Strategy for tracking the fate of 2HG. a Successful synthesis of U-13C 2HG is supported by accurate mass measurements and tandem mass
spectra. b Metabolomic platform for unbiased tracking of isotopes. Cells were grown in parallel cultures, with and without labeled substrate (n = 3
per group). Metabolites were extracted from the cells and analyzed by LC/MS. The data were processed by using our in-house X13CMS software,
which is designed to unbiasedly find differences in isotopic enrichment. These differences correspond to labeled compounds that are possible
biotransformations of the labeled substrate provided. Here, we show the isotopologue patterns for 2HG, which had an isotopic enrichment of
35 % in labeled samples. Metabolites of interest were identified by accurate mass, tandem mass spectra, and our isoMETLIN database
Fig. 1 Conventional untargeted metabolomic comparison of parent HCT116 colorectal carcinoma cells to isogenic cells with heterozygous knock-in
of the R132H IDH1 mutant. Results are based on n = 3 samples per group. a Each circle displayed represents a metabolomic feature detected. Features
off the y = x line have altered intensities between groups. Out of the 12,481 features detected, we found that 1722 were altered with p values <0.05
and fold changes >1.5. These data support that mutant IDH1, perhaps through the production of D-2HG, affects the metabolic phenotype of colorectal
carcinoma cells and therefore are a reasonable choice to study 2HG metabolism. We identified the feature shown in green as 2HG, which was
increased in HCT116 cells by a fold change of 165 to approximately 3.5 mM. b Box plots comparing the levels of selected metabolites
between IDH1 mutant and wild type cells
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Fig. 3 Global mapping of 2HG and glutamine fate. Plots showing altered metabolomic features in colorectal carcinoma cells after introduction
of either a labeled U-13C 2HG (n = 3 per group) or b U-13C glutamine (n = 3 per group) for 24 h. The data shown are from colorectal carcinoma
cells harboring mutations in IDH1. The y axis shows the fold change of isotopic enrichment calculated by dividing the intensity of each feature in
the labeled samples by the intensity of each feature in the non-labeled samples. Features found to be enriched are shown with enlarged circles for
clarity. Features containing isotopic label, shown in red on the left, were determined to be adducts or fragments of 2HG. The inset shows the extracted
ion chromatogram (i.e., the LC trace) of each feature related to 2HG, each having the same retention time and chromatographic shape as expected for
adducts and fragments. In contrast to the 2HG experiment where no labeled products were detected, the label from glutamine was incorporated into
hundreds of features. One of the labeled features is annotated as 2HG. The glutamine data serve as a positive control that our platform can successfully
identify biotransformations of a labeled substrate
Fig. 4 Exogenous 2HG enters cells, but is not metabolized at significant levels by 2HG dehydrogenase. a After treating HCT116 R132H/+
cells with U-13C 2HG for 24 h, we measured intracellular 2HG by mass spectrometry and found that 35 % was enriched. These data show
that exogenous U-13C 2HG enters the cells. b An ELISA experiment confirmed that D-2HG dehydrogenase is present in HCT116 R132H/+
cells. c–e More sensitive targeted mass spectrometry methods were applied to measure low levels of isotopic enrichment in central carbon
metabolites. f HCT116 parent cells were cultured in 3 mM D-2HG and compared to media preparations without cells as a control for spontaneous
non-cellular degradation of 2HG. After 48 h, we found no statistically significant consumption of 2HG from the media (see Table 1). These data support
that 2HG is not readily metabolized in HCT116 cells
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As expected, one metabolite we identified as a product
of glutamine was 2HG. Further analysis of glutamine
transformation is beyond the scope of the current study,
but the data can be viewed at the NIH metabolomics
workbench or on our laboratory website (http://goo.gl/
W4rbu1).
Targeted screening of predicted 2HG products shows
trace levels of enrichment
The enzyme D-2HG dehydrogenase converts D-2HG
into alpha-ketoglutarate. Given that our unbiased meta-
bolomic screen did not reveal any 2HG transformations,
we wanted to validate that D-2HG dehydrogenase was
present in our HCT116 R132H/+ cells. We confirmed
the presence of D-2HG dehydrogenase by ELISA
(Fig. 4b). The level of D-2HG dehydrogenase we mea-
sured in HCT116 R132H/+ cells was 4.7 ± 0.96 ng/mL,
which was comparable to the value we measured in
HeLa cells where D-2HG dehydrogenase has been previ-
ously reported [20].
To assess the possibility that D-2HG dehydrogenase
converts labeled 2HG into labeled alpha-ketoglutarate at
a concentration below the limit of detection of our glo-
bal profiling platform, we performed a targeted LC/MS-
based experiment and evaluated isotopic enrichment
manually. Compared to global profiling analyses, tar-
geted SIM experiments have improved sensitivity and
therefore are able to better detect low levels of isotopic
enrichment. We found that alpha-ketoglutarate was
enriched in HCT116 R132H/+ cells given U-13C 2HG by
approximately 1 % (Fig. 4c). We detected alpha-
ketoglutarate with five 13C labels (0.9 %) and three 13C
labels (0.1 %). The latter labeling pattern results from
2HG-derived alpha-ketoglutarate after one turn of the
TCA cycle. We also detected trace amounts of label-
ing (<0.5 %) in other TCA cycle metabolites such as
citrate/isocitrate and glutamine (Fig. 4d–e). We
should point out that we cannot dismiss the possibil-
ity that some (or all) of this labeling results from U-
13C alpha-ketoglutarate in our U-13C 2HG stock solu-
tion (i.e., residual starting material after synthesis) or
spontaneous, non-cellular degradation of U-13C 2HG.
Nonetheless, these labeling results place a ~1 % upper
limit on the contribution of labeled 2HG to TCA
cycle carbon at 24 h.
Total accounting of net 2HG consumption from media
To evaluate the possibility that 2HG label is trans-
formed into a metabolic product that we do not
detect, we incubated parent HCT116 cells in 3 mM
D-2HG for 48 h. After 24 and 48 h, we measured the
total level of D-2HG remaining in the media. We did
not detect a statistically significant decrease in the
concentration of D-2HG between control media and
media containing HCT116 cells at either time point
(Fig. 4f). The small decrease in 2HG concentration be-
tween time points was not a result of cellular 2HG trans-
formation but rather due to non-cellular 2HG degradation
with time. In contrast, we observed a significant decrease
in glutamine media levels over 48 h (Table 1). We deter-
mined that glutamine was consumed by cells at a rate of
~0.15 pmol/cell/h. We did not detect any statistically sig-
nificant cellular consumption of 2HG above the detection
limit of our assay (which we determined to be approxi-
mately 1 fmol/cell/h).
Exogenous 2HG does not influence TCA cycle labeling
patterns from U-13C glucose
We predicted that U-13C 2HG given to colorectal car-
cinoma cells would be degraded by 2HG dehydrogenase
enzymes to yield 13C-labeled alpha-ketoglutarate, which
would then be metabolized by other pathways such as
the TCA cycle. Yet, our metabolomic screens suggest
that labels in U-13C 2HG are not significantly metabo-
lized over a 24 h time course. To further support these
results, we pursued a complementary U-13C glucose
labeling experiment. In brief, we gave colorectal carcin-
oma cells U-13C glucose and then monitored labeling of
TCA cycle intermediates when the cells were treated
with 2HG for 24 h. We performed the experiments with
either 2.5 or 5 mM of L-2HG, 2.5 or 5 mM of D-2HG,
or a 5 mM racemic mixture of L-2HG and D-2HG. The
labeling patterns of TCA cycle intermediates from U-13C
glucose were not statistically different upon the addition
of 2HG to the culture media (Fig. 5). Our results were
comparable in the parent cells and cells harboring mu-
tant IDH1. Since the isotopic labeling percentages of
TCA cycle intermediates from U-13C glucose were not
diluted by insertion of non-labeled 2HG carbons as
alpha-ketoglutarate, the findings were consistent with
the metabolomic data described above and support that
2HG is not significantly metabolized. Notably, TCA
cycle intermediate labeling from U-13C glucose was not
significantly different between cells that were given L-
2HG, D-2HG, or racemic mixtures of both. This sug-
gests that having a high concentration of both L-2HG
and D-2HG simultaneously, such as the racemic mixture
Table 1 2HG and glutamine consumption in wild type HCT116
cells
2HG Glutamine
Consumption rate Below detection of assaya ~0.15 pmol/cell/h
% Consumed Below detection of assay ~97 %
p value >0.2 <0.001
aWe determined the detection limit of our assay to be
approximately 1 fmol/cell/h
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we synthesized, does not influence the carbon metabol-
ism of either isomer.
It is important to clarify that the experiments de-
scribed above involving U-13C glucose were not designed
to assess the metabolic effects of 2HG. Although the iso-
topic enrichment plots in Fig. 5 show no significant dif-
ferences in the labeling of central carbon metabolites
upon treatment with 2HG for 24 h, these data do not
provide information on absolute fluxes or relative pool
sizes. It is not our intent to suggest that metabolism is
unaffected by 2HG.
Discussion
L-2HG and D-2HG occur naturally at low concen-
trations (<100 μM) in healthy mammalian cells [2].
In multiple cancers, the concentration of D-2HG in-
creases substantially to mM levels as a result of
gain-of-function mutations in IDH [10]. It has been
shown that alterations in either L-2HG or D-2HG
concentrations can have important functional conse-
quences [7, 9]. Accordingly, much attention has been
devoted to elucidating the biochemical routes of
2HG synthesis. However, the metabolic fate of 2HG
has not been investigated comprehensively. Yet the
pathway of 2HG transformation plays a relevant role
in modulating 2HG levels and was therefore the
focus of the current work. Additionally, we wanted
to explore the possibility that 2HG is transformed
into metabolic products with unique biochemical ac-
tivities contributing to 2HG-related phenotypes.
We performed several separate experiments indicating
that 2HG is not readily metabolized in colorectal cancer
cells, independent of whether the cells harbor the
R132H-IDH1 mutation. First, we fed cells U-13C 2HG
and monitored thousands of metabolomic features for
13C label incorporation. After 24 h, we observed no
labeled features other than those arising from 2HG
(Fig. 3a). A more sensitive targeted analysis revealed trace
levels of isotopic enrichment in some central carbon me-
tabolites (Fig. 4c–e). By monitoring 2HG consumption,
however, we showed that these transformations do not
represent a statistically significant percentage of 2HG car-
bon (Fig. 4f). In an independent experiment, we fed
cells U-13C glucose and monitored the isotopic labeling of
TCA cycle intermediates upon addition of L-2HG, D-
2HG, or racemic mixtures of both. We observed no
significant labeling differences in cells treated with 2HG,
indicating that any 2HG inserted into the TCA cycle is
below the sensitivity limit of this experiment (Fig. 5).
The subject of how elevated 2HG levels contribute to
cellular transformation and tumorigenesis has been an
area of intense interest. The mechanism that perhaps has
been best supported thus far is epigenetic regulation by in-
hibition of alpha-ketoglutarate-dependent enzymes. Given
the structural and chemical similarity of 2HG to alpha-
ketoglutarate, L-2HG and D-2HG can competitively
inhibit alpha-ketoglutarate-dependent dioxygenases that
modify chromatin [5]. These effects have been associated
with alterations in growth and cellular differentiation [13].
This mechanism of 2HG-mediated epigenetic regulation
is dependent upon the concentration of 2HG and has
been well correlated with rates of 2HG synthesis [11, 15].
Our results are consistent with this model.
Another possible mechanism of 2HG action that has
not been explored to date is that a downstream product of
2HG, possibly a previously uncharacterized metabolite,
Fig. 5 Exogenous 2HG does not influence TCA cycle labeling from
U-13C glucose. As further support that significant amounts of 2HG
are not metabolized into TCA cycle intermediates, we performed an
experiment that had a reverse labeling scheme compared to that
experiment shown in Fig. 2. U-13C glucose was given to cells and the
labeling patterns of TCA cycle intermediates monitored as a function
of L-2HG, D-2HG, or racemic mixtures of L- and D-2HG administration.
Here, we show isotopologue distributions of metabolites from
HCT116 R132H/+ cultures given U-13C glucose + D-2HG and from
parent cultures given U-13C glucose and no 2HG. Isotopologue
distributions were evaluated for TCA cycle intermediates and
related compounds, three of which are displayed. No differences in
isotopologue distributions were found to be statistically significant
in these experiments (n = 3 per group) or those performed with
the L-2HG enantiomer (n = 3 per group) and the racemic mixture
of 2HG (n = 3 per group)
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has unique biochemical activity. Our results do not sup-
port this model. By using untargeted metabolomic tech-
nologies, we screened over 25,000 features as potential
2HG products and obtained no leads. It may be possible
that 2HG is metabolized to a compound not detected
by LC/MS (e.g., macromolecules, low-concentration
metabolites, etc.). However, we have shown previously
that our metabolomic platform has broad coverage
(for both polar and non-polar molecules) and high
sensitivity for detecting metabolites with structures
similar to 2HG as would be anticipated for the prod-
ucts of interest [21, 29]. Moreover, after 48 h, we
have shown that there is no statistically significant
consumption of 2HG above our assay detection limit
of ~1 fmol/cell/h (Fig. 4e).
It is important to emphasize that our results are from
only a single colorectal carcinoma cell line. Although we
do not see evidence that 2HG is readily transformed
here, such pathways may exist in other cell lines or cell
types. Additionally, given that 2HG can be imported and
exported from cells, it is also possible that 2HG pro-
duced from the tumors of whole animals is ultimately
cleared from the organism even when the cancer cells
producing 2HG cannot metabolize it.
Conclusions
Intracellular concentrations of L-2HG and D-2HG are
known to regulate cellular physiology by mechanisms
that are incompletely understood. Critical to under-
standing how 2HG concentrations are controlled is the
elucidation of pathways of 2HG synthesis and pathways
of 2HG transformation. While the former has been in-
vestigated extensively, here we provide the first compre-
hensive assessment of the latter. Our results indicate
that L-2HG and D-2HG are not readily metabolized in
HCT116 colorectal carcinoma cells. Future work will
explore the metabolism of 2HG in other cell types and
culture conditions.
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